Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: A pilot study

Annals of Hematology

Volumn 80, Issue 7, 2001, Pages 411-416

  Niitsu, N ^a   Iijima, K ^a   Chizuka, A ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CPT 11; Mitoxantrone; Non Hodgkin's lymphoma; Relapsed

Indexed keywords

ANTIBIOTIC AGENT; BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; MITOXANTRONE; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; VINCRISTINE;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BRONCHOPNEUMONIA; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEMATURIA; HUMAN; MALE; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTPATIENT CARE; PILOT STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEXAMETHASONE; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS;

EID: 0034908337     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770100313     Document Type: Article

References (24)

1. Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential
2. DNA topoisomerases: Essential enzymes and lethal targets
3. Mitoxantrone in refractory non-Hodgkin's lymphoma
4. Topoisomerase I inhibitors: Topotecan and irinotecan
5. An EORTC phase II study of mitoxantrone in solid tumors and lymphomas
6. Combination therapy of CPT-11, a camptothecin derivative, with various antitumor drugs against L1210 leukemia
7. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
8. Effects of CPT-11 in combination with other anti-cancer agent in culture
9. Nonparametric estimation from incomplete observation
10. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect CPT-11
11. Experiment studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice
12. Combination cancer chemotherapy using a DNA topoisomerase inhibitor CPT-11, as a core agent - The in vitro evaluation
13. An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with hematological malignancies
14. Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia
15. Toxicity and response criteria of the Eastern Cooperative Oncology Group
16. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer
17. DNA topoisomerase I and II in cancer chemotherapy: Update and perspectives
18. Combination chemotherapy with irinotecan and adriamycin for refractory or relapsed non-Hodgkin's lymphoma
19. International non-Hodgkin's lymphoma prognostic factors project: A predictive model for aggressive non-Hodgkin's lymphoma
20. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of working formulation for clinical usage
21. Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma
22. Combination phase I study of irinotecan hydrochloride combined with etoposide in refractory or relapsed non-Hodgkin's lymphoma
23. Antitumor effect of CPT-11, a new derivative of camptothecin against pleiotropic drug-resistant tumors in vitro and in vivo